Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Frontier Biotech Raises $29 Million for Novel COVID-19 Therapy

publication date: Sep 9, 2022

Nanjing Frontier Biotechnologies completed a $29 million private placement to underwrite development of its novel small molecule for COVID-19, bofutrelvir (FB2001). Bofutrelvir is a SARS-CoV-2 3CL protease inhibitor currently in clinical trials for hospitalized patients in need of post-exposure COVID-19 prophylaxis. Founded in 2013, Frontier is a commercial-stage biopharma that focusing on unmet medical needs for anti-HIV treatment and pain management. A total of 19 investors participated in the funding included Lord Abbett, UBS AG and Aeon Life. More details....

Stock Symbol: (SHA: 688221)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital